Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 7 consecutive quarters of double digit growth. Click here to learn more ›

Conditional cardiomyocyte-restricted CorinKO mice demonstrate increased cardiac hypertrophy and pro-fibrotic gene activation in response to TAC and PL-3994-a novel selective GC-A receptor peptide agonist rescues the phenotype

Scroll to Top